Mouse Anti-GPRC5D Recombinant Antibody (CBLG1-208) (CBMAB-G0732-LY)

Zhang, M., Wei, G., Zhou, L., Zhou, J., Chen, S., Zhang, W., ... & Huang, H. (2023). GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. The Lancet Haematology, 10(2), e107-e116.

Nath, K., Costa, B. A., & Mailankody, S. (2023). GPRC5D as a novel immunotherapeutic target in multiple myeloma. Nature Reviews Clinical Oncology, 1-2.

Mailankody, S., Devlin, S. M., Landa, J., Nath, K., Diamonte, C., Carstens, E. J., ... & Smith, E. L. (2022). GPRC5D-targeted CAR T cells for myeloma. New England Journal of Medicine, 387(13), 1196-1206.

Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W., Rodríguez-Otero, P., ... & Krishnan, A. (2022). Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. New England Journal of Medicine, 387(24), 2232-2244.

Berdeja, J. G., Krishnan, A. Y., Oriol, A., van de Donk, N. W., Rodríguez-Otero, P., Askari, E., ... & Chari, A. (2021). Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)× CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

Mailankody, S., Diamonte, C., Fitzgerald, L., Kane, P., Wang, X., Sikder, D. S., ... & Smith, E. L. (2021). Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma. Blood, 138, 827.

Chari, A., Berdeja, J. G., Oriol, A., van de Donk, N. W., Rodriguez, P., Askari, E., ... & Krishnan, A. (2020). A phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody, in patients with relapsed and/or refractory multiple myeloma (RRMM). Blood, 136, 40-41.

Fernández de Larrea, C., Staehr, M., Lopez, A. V., Ng, K. Y., Chen, Y., Godfrey, W. D., ... & Smith, E. L. (2020). Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple MyelomaAddressing BCMA Escape with Dual-Targeted CAR T-cell Therapy. Blood Cancer Discovery, 1(2), 146-154.

Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., ... & Brentjens, R. J. (2019). GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Science translational medicine, 11(485), eaau7746.

Kodama, T., Kochi, Y., Nakai, W., Mizuno, H., Baba, T., Habu, K., ... & Akashi, K. (2019). Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple MyelomaAnti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody. Molecular cancer therapeutics, 18(9), 1555-1564.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols